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Abstract
Rationale: Lymphatic malformations (LMs) are rare and benign anomalies resulting from the defective embryological development
of the primordial lymphatic structures. Due to their permeative growth throughout all tissue layers, treatment is often challenging.
Small asymptomatic lesions can be conservatively managed, while symptomatic lesions require active management. Surgery has
been historically considered the treatment of choice, but today less invasive therapeutic options are preferred (sclerotherapy, laser
therapy, oral medications). However, there are not uniform therapeutic protocols. Sirolimus is an oral medication that has been
reported to be effective in the recent literature. Here we present the case of 4 newborns with giant multicystic lymphangioma treated
with oral sirolimus after surgical resection had failed.
Patient concerns: At birth the LMs were clinically appreciated as giant masses involving different organs and structures.
Diagnoses:All patients had a prenatal diagnosis of giantmulticystic lymphangioma conﬁrmed at histological and cytological analysis.
Interventions: Patients were treated with oral sirolimus after unsuccessful surgical resection.
Outcomes: In all patients, sirolimus determined an overall reduction of the mass and a global involution from the macro- to the
microcystic composition. Sirolimus was safe and poor disadvantages had been observed. The main and isolated adverse effect at
laboratory analysis was progressive dyslipidemia, with increasing levels of total cholesterol and triglycerides.
Lessons: To date, our experience with sirolimus in the management of LMs is favorable. We recommend the use of sirolimus after
unsuccessful surgical excision have been tried or when the surgical approach is not feasible. Amultidisciplinary follow-up is needed to
monitor disease evolution.
Abbreviations: DOL = day of life, EXIT = ex utero intrapartum treatment, LMs = lymphatic malformations, MRI = magnetic
resonance imaging.
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1They consist of dilated lymphatic channels formingmultiple cysts of
variable size (macro- or microcystic lymphangioma).[1,2]
Due to their permeative growth throughout all tissue layers,
treatment is often challenging. Surgical excision has been
historically considered the treatment of choice, but today less
invasive therapeutic options are preferred. Sirolimus is an oral
medication that has been reported to be effective in the recent
literature.[2,3]
Sirolimus (rapamycin) is an immunosuppressive and antitumor
agent which belongs to the mammalian target of rapamycin
(mTOR) inhibitors group. The mTOR/PI3K pathway has been
demonstrated to be involved in vascular development. Activation
ofmTORsignaling increases the expressionof vascular endothelial
growth factor A and C (VEGF-A and VEGF-C), key regulators of
angiogenesis and lymphangiogenesis respectively, promoting cell
growth and vascular proliferation. Sirolimus can inhibit abnormal
vascular proliferation by blocking the mTOR/PI3K pathway and
by reducing the production of VEGF and responsiveness of its
receptors.[4–9] Its most signiﬁcant adverse effects are thrombocy-
topenia, rash, asthenia, nausea, edema, anorexia, anemia,
hyperglycemia, hyperlipemia, hypertriglyceridemia, elevated alka-
line phosphatase, elevated serum creatinine, lymphopenia,
hypophosphatemia. Rare but potentially serious side effects
associated with the use of sirolimus have also been described,
such as infections and cardiac disorders.[10,11]
Table 1
Patients characteristics.
Case 1 Case 2 Case 3 Case 4
History
Prenatal diagnosis Multicystic lymphangioma Multicystic lymphangioma Multicystic lymphangioma Multicystic lymphangioma
Prenatal complications — Airways compression Airways compression, hydrothorax Airways compression
Delivery location Inborn Inborn Inborn Inborn
Delivery mode CS+EXIT CS+EXIT CS+EXIT CS+EXIT
Nationality of parents Tunisia Italy Italy Italy
Sex Male Male Male Female
Gestational age 36 wk+3 d 35 wk+6 d 35 wk 38 wk+3 d
Birth weight 3825g 3060g 2750g 3370g
APGAR 10/50 8/10 7/7 2/8 6/7
Days of MV 1 42 22 62
Days of NIV 0 0 10 2
Clinical ﬁndings
Physical examination Left posterior hemithorax and right
gluteus mass, bluish discoloration
of the skin
Left cervical mass, bluish
discoloration of the skin
Left cervical mass, normal skin Left cervical mass, normal skin
Radiological ﬁndings US and MRI with contrast:
multicystic lymphangioma
US and MRI with contrast:
multicystic lymphangioma
US and MRI with contrast:
multicystic lymphangioma
US and MRI with contrast:
multicystic lymphangioma
Localization Thorax, abdomen (intra- and
retroperitoneal extension)
Face, neck, thorax (upper
mediastinum, left supraclavear
region)
Neck, thorax (upper mediastinum) Neck, thorax (upper mediastinum,
left supraclavear region)
Organs involved in the diagnosis Inferior vena cava, aorta, right renal
artery, iliac arteries, right kidney,
liver
Cervical muscles, tongue basis,
trachea, larynx
Cervical muscles, vascular nervous
fascia, retropharyngeal space,
trachea, larynx
Cervical muscles, vascular nervous
fascia, retropharyngeal space,
trachea, larynx, thymus, thoracic
arteries, superior vena cava,
heart
Maximum diameter of the cysts 4 cm 5cm 3cm 3cm
Complications Intracystic bleeding Intracystic bleeding, airways
obstruction
Airways obstruction Intracystic bleeding, airway
obstruction, heart displacement
Tumor markers Not relevant Not relevant Not relevant Not relevant
Blood routine analysis Not relevant Not relevant Not relevant Not relevant
Surgical treatment
Time of intervention 2 mo of life 10 d of life 2 wk of life 2 mo of life
Surgery Drainage of cyst liquid Surgical resection Surgical resection Surgical resection
Histology/cytology Fibrin, lymphocytes, histiocytes,
RBCs, no tumor cells
Cystic lymphangioma Cystic lymphangioma Cystic lymphangioma
Results Partial reduction of mass extension Partial reduction of mass extension Partial reduction of mass extension Partial reduction of mass extension
Complications No Facial palsy No No
Relapse No Yes Yes No
Time of relapse — 3 wk after 18 mo after —
Characteristics — New cysts from the residual
lymphangioma





Laser therapy No Yes No No
Tracheostomy No Yes No No
Other — CO2 laser Thoracic drainage First sirolimus treatment for 5 wk
before surgical intervention.
Fluctuating blood levels, no
clinical improvement
Sirolimus treatment
Time of intervention 3 mo of age 16 mo of age 23 mo of age 2.5 mo of age
Dosage 0.4–0.8mg/m2 2 times/d 0.4–0.8mg/m2 2 times/d 0.4–0.8mg/m2 2 times/d 0.4–0.8mg/m2 2 times/d
Clinical ﬁndings Reduction of mass size Reduction of mass size Reduction of mass size Reduction of mass size
Radiological ﬁndings MRI with contrast: reduction of mass
size, prevalence of microcystic
elements
MRI with contrast will be soon
performed
MRI with contrast: reduction of mass
size, prevalence of microcystic
elements
MRI with contrast: reduction of mass
size, prevalence of microcystic
elements
Averse effects
Anemia No No No No
Leucopenia No No No No
Thrombocytopenia No No No No
Dyselectrolytemia No No No No
Renal failure No No No No
Dyslipidemia Yes No Yes Yes
Fever No No No No
Infections/sepsis No No No No
Rash No No No No
Hypotension No No No No
Hypertension No No No No
Gastrointestinal symptoms No No No No
Other No No No No
Ongoing treatment Yes Yes Yes Yes
CS= cesarean section, EXIT= ex utero intrapartum treatment, MRI=magnetic resonance imaging, MV=mechanical ventilation, NIV=noninvasive ventilation, RBCs= red blood cells, US=ultrasound.
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Amodeo et al. Medicine (2017) 96:51 www.md-journal.comWe present the cases of 4 newborns with giant multicystic
lymphangioma treated with oral sirolimus after surgical resection
had failed.The characteristics of the4newborns are summarized in
Table 1.The diagnosis and treatmentof all caseswereperformed in
the Neonatal Intensive Care Unit of Fondazione IRCCS Cà
Granda, Ospedale Maggiore Policlinico (Milan, Italy) from 2014.2. Case reports
2.1. Case 1
A male baby was born by cesarean section for labor starting at 36
weeks of gestation. The lesion was ﬁrst detected at the prenatal
ultrasound. The mass extended from the posterior area of the neck
to the lower abdomen but did not seem to determine airways
obstruction. At birth ex utero intrapartum treatment (EXIT) was
performed, with no complications. APGAR score was 8/10 and
birth weight 3825g. At physical examination, a purple vascular
mass involving the left posterior hemithorax and the right gluteus
was present.Magnetic resonance imaging (MRI) scanwith contrast
showed thoracic andabdominal cystic formationswith corpuscular
content, which inﬁltrated the thoracic and the abdominal wall,
including the diaphragm. Lesions involved multiple vessels and
organs (inferior vena cava, aorta, right renal artery, iliac arteries,
right kidney, liver), reached the right inguinal area and also had a
retroperitoneal extension. All MRI scan characteristics conﬁrmed
the diagnosis of multicystic lymphangioma (Fig. 1A). Blood
analyses were normal, and the principal tumor markers were not
relevant. Since the mass did not determine airways obstruction, no
surgical intervention was made until the age of 2 months. During
the procedure, a big cyst localized in the left hemithorax was
drained. At MRI scan with contrast performed 1 month after
surgical drainage, the left part of the lymphangiomawas reduced in
volume, but the rest of the mass was unchanged (Fig. 1B).
At 3 months of age, given the persistence of multiple lesions
and the risk of further growth, pharmacological therapy with
sirolimus was started. The dosage was 0.4 to 0.8mg/m2 2 times/
day, adjusted to maintain sirolimus blood levels between 10 and
15ng/mL. After 3 months of treatment, an MRI scan with
contrast was performed, which documented a signiﬁcant
reduction in mass size and a global involution of the cysts to
microcystic or stromal elements (Fig. 1C). Then, a clinical,
radiological, and pharmacological follow-up was started, which
documented a progressive improvement. The only adverse effect
observed was moderate dyslipidemia with high levels ofFigure 1. T2-weighted MR images performed at different times. Thoracic and
abdominal cysts, with retroperitoneal extension, which were present at birth
(A). The overall size was 6cm12cm, with the bigger elements of about 4cm
in diameter. MR image performed after surgical drainage demonstrate that the
bigger cyst was reduced in diameter, but the rest of the mass was unchanged
(B). After 3 months of sirolimus treatment, a signiﬁcant reduction in mass size
and a global involution of the cysts was obtained (C).
3cholesterol and triglycerides started after 6 months of treatment.
The patient is currently on clinical, pharmacological, and
radiological follow-up and the treatment is still ongoing.2.2. Case 2
A male baby was born by cesarean section at 35+6 weeks of
gestation. A fetal ultrasound performed at 31 weeks of gestation
showed the presence of a left cervicofacial mass. Fetal MRI scan
conﬁrmed the diagnosis of giant multicystic lymphangioma
displacing the trachea and the larynx (Fig. 2A). Therefore, EXIT
was performed at birth, and the patient was maintained on
mechanical ventilation for the next 6 weeks. APGAR score was 7/7
andbirthweightwas3060g.Atphysical examination, abigvascular
mass was appreciated in the left cervical region. On days of life
(DOL) 1, anMRI scanwith contrast showed amulticameralmass in
the left cervical region. It developedamongmuscular planes, reached
the root of the tongue and inﬁltrated thedeep tissues near the trachea
and the larynx. The trachea was displaced contralaterally (Fig. 2B).
Blood analyses were normal, and the principal tumor markers were
not relevant. On DOL 10, the patient underwent a surgical
intervention, although a complete resection was not possible.
Intraoperative biopsy conﬁrmed the diagnosis of multicystic
lymphangioma. Three weeks after, the MRI scan with contrast
showed new cystic formations on the root of the tongue, in the
retropharyngeal space and on the mucosal surface of the larynx
(Fig. 2C). The laryngeal relapse was treated with CO2 laser,
obtainingagoodcanalizationof the airways.At6monthsof life, due
to the progressive growth of the lesions, a tracheostomy became
necessary. In consideration of the relapsing course and the diffuse
localization, at 16 months of age pharmacological therapy with
sirolimus was started. The dosage was 0.4 to 0.8mg/m2 2 times/day
with sirolimus blood levels to be maintained between 10 and 15ng/
mL. Despite a gradual increase of the dosage, there were difﬁculties
withmaintaining blood concentrations in the therapeutic range, and
they were often underdosed (<10ng/mL). No alterations of routine
blood analysis have been observed. The patient is currently on
clinical, pharmacological, and radiological follow-up and the
treatment is still ongoing.
2.3. Case 3
At 29 weeks of gestational age, a multicystic mass of 4.8cm3.8
cm in the left cervical and upper mediastinal region was detected
at the fetal ultrasound. During the following weeks of gestation,Figure 2. Fetal MRI image shows the presence of giant cervical multicystic
lymphangioma (A). 3D reconstruction MRI performed at birth showed several
cystic elements inﬁltrating the root of the tongue and the deep tissues near the
trachea and the larynx. Themaximum diameter was 4cm (B). Three weeks after
surgical resection, new cystic formations appeared in the cervical region (C).
Amodeo et al. Medicine (2017) 96:51 Medicinethe mass progressively enlarged and the fetus developed left
hydrothorax, with compression on airways and displacement of
the trachea. For these reasons, this male baby was born by urgent
cesarean section and EXIT at 35 weeks of gestational age.
APGAR score was 2/8. Birth weight was 2750g. Immediately
after birth, hydrothorax was drained, and a thoracic catheter was
left in situ for 26 days. The patient wasmaintained onmechanical
ventilation for 22 days and then on noninvasive ventilation for 10
days. At physical examination, a signiﬁcantmass was appreciated
in the left cervical region. At MRI scan performed at DOL 6,
several lacunas were observed in the left cervical region, involving
the retropharyngeal space and displacing the trachea and the
larynx contralaterally. The mass occupied the mediastinum until
the carena. The sternocleidomastoideus muscle and the vascular
nervous fascia of the neck were inﬁltrated and compressed
(Fig. 3A). Blood analysis was normal, and the principal tumor
markers were not relevant. At 2 weeks of life, given the
compression of vital structures, surgery was performed, but
complete resection was not possible (Fig. 3A). Biopsies conﬁrmed
the diagnosis of multicystic lymphangioma. A clinical, pharma-
cological, and radiological follow-up was started. Eighteen
months later, the MRI documented a relapse of the lymphan-
gioma (Fig. 3B). The spleen appeared enlarged and completely
inﬁltrated by millimetric cysts. Moreover, the presence of
multiple focal hyperintense anomalies in bone, with no associated
edema, was detected for the ﬁrst time. These anomalies involved
different skeletal segments (humerus bones, scapulae, dorsal
vertebrae, some ribs, sphenoid, maxilla). In consideration of the
continuous evolution and the multiple bone involvement, neither
surgical resection nor sclerotherapy were feasible. Then, at 23
months of age pharmacological therapy with sirolimus was
started. The dosage was 0.4 to 0.8mg/m2 2 times/day. The
desired blood levels were between 10 and 15ng/mL. A clinical,
pharmacological, and radiological follow-up was then started.
Despite good compliance, there were difﬁculties withmaintaining
blood levels in the therapeutic range and they were often
underdosed. At the MRI scan with contrast performed after 6
months of treatment, an overall reduction of the cysts and the
spleen diameter was appreciated (Fig. 3C). Bone involvement was
essentially stable, with no further progression. After 6 months of
treatment with sirolimus, the patient developedmild dyslipidemia
with high levels of cholesterol and triglycerides. The patient is
currently on clinical, pharmacological, and radiological follow-
up and the treatment is still ongoing.Figure 3. T2-weighted MR images performed at different times. At 6 days of
life, several cysts were present in the left cervical region, involving the
retropharyngeal space and displacing the trachea and the larynx contral-
aterally. The mass involved the sternocleidomastoideus muscle and the
vascular nervous fascia of the neck and occupied the mediastinum until the
carena (A). Eighteen months after surgery, a relapse of the lymphangioma was
documented in the right supraclavear region. The presence of multiple
anomalies in bone signal was detected for the ﬁrst time (B). After 6 months of
sirolimus treatment, an overall reduction of the cysts was appreciated, while
bone involvement was essentially stable (C).
42.4. Case 4
A female baby was delivered by an elective cesarean section with
EXIT procedure at 38 weeks+3 days of gestational age after a
multicystic LM had been diagnosed at the fetal ultrasound. Birth
weight was 3370g, and APGAR score was 6/7. The patient was
maintained on mechanical ventilation for 62 days after birth. At
physical examination, a big soft mass was appreciated in the left
cervical region and the upper portion of the left anterior thorax.
On DOL 7, anMRI scan with contrast was performed. The mass
originated in the left cervical area and inﬁltrated several
structures (left sternocleidomastoideus muscle, left vascular
nervous fascia, occipital muscles, larynx, pharynx). Cysts were
in contact with the posterior trachea, thoracic arteries, superior
vena cava, and thymus. The mediastinal mass slightly displaced
the heart, but no signiﬁcant compression on the great vessels was
detected (Fig. 4A). Given the broad distribution of the cysts and
the high probability of surgical failure, treatment with sirolimus
was started on DOL 13. Due to the difﬁculties with maintaining
the desirable sirolimus levels, therapy was often discontinued,
and no clinical improvement was obtained. For this reason, the
patient underwent a partial resection of the mass at 2 months old.
Biopsies conﬁrmed the diagnosis of multicystic lymphangioma.
After surgery, a consistent reduction in the mass size was
appreciated, enabling themechanical ventilation to be suspended.
Two weeks after surgery sirolimus therapy was restarted. The
dosage was 0.4 to 0.8mg/m2 2 times/day, calculated to maintain
sirolimus blood levels between 10 and 15ng/mL. A progressive
reduction and stabilization of the mass were clinically observed.
After 2 months of treatment, the MRI scan with contrast
documented an overall involution tomicrocystic lesions (Fig. 4B).
As the isolated adverse effect of sirolimus treatment, the patient
developed mild dyslipidemia with high levels of cholesterol. The
patient is currently on clinical, pharmacological, and radiological
follow-up and the treatment is still ongoing.
2.5. Timeline
Figure 5 summarizes the main clinical and radiologic ﬁndings in
our patients, which led to the diagnosis of giant cystic
lymphangioma, and the major steps in the management and
follow-up.Figure 4. T2-weighted MR images performed at different times. At birth a giant
lymphangioma was present in the left cervical area and mediastinum, inﬁltrating
several structures (left sternocleidomastoideus muscle, left vascular nervous
fascia, occipital muscles, larynx, pharynx). Airways were displaced (A). After a
ﬁrst surgical approach and 2 months of sirolimus treatment, an overall
involution of the mass was documented (B).
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Figure 5. Patients’ main clinical and radiologic ﬁndings which led to the diagnosis of giant cystic lymphangioma. Main steps in the management and follow-up are
also reported.
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Most of the lymphangiomas are typically present at birth and are
often diagnosed prenatally. In general, 80%of these malformations
are diagnosedbefore the ageof 2years.[12] The cervicofacial region is
most affected (approximately 50–75%).[13] They can also be found
in the trunk, axilla, and extremities (42%). The mediastinal and
abdominal locations are rare (10%).[2,14] Due to their permeative
growth throughout all tissue layers, treatment is often challenging.
The goal of LM management and treatment is to maintain
functionality, control associated symptoms, and preserve aesthetic
integrity.[2] In all cases, the treatment decision should be individual-
ized and based on several factors, such as the type of malformation,
size, location, growing trend, and associated symptoms.[1]
Surgical excision has been historically considered the treatment
of choice for macrocystic and unicameral LMs, but resection is
often incompletewith several complications (in particular bleeding,
iatrogenic damages, and deformity) and high recurrence rate.[15]
Today less invasive therapeutic options are preferred. Small
asymptomatic lesions can be carefully monitored since the
possibility of spontaneous regression is described.[2,16–25] In other
cases, sclerotherapy, laser therapy, and pharmacological treat-
ment can be considered.[18,19]
Sildenaﬁl, sirolimus, and propranolol are 3 oral medications
that have been reported to be effective in the recent literature in
the treatment of vascular anomalies.[3,21]
In particular, sirolimus has been demonstrated to be an
efﬁcacious and safe treatment for patients with complicated
vascular anomalies, included cystic lymphangiomas and
diffuse lymphangiomatosis that were refractory to other
therapies.[3,22,23]5In our case series, patients were affected by giant cystic
lymphangioma with multiple organ involvements (case 3).
Surgical resection was performed primarily to relieve the airway
obstruction and to prevent further complications, such as
intracystic bleeding, cysts infection, nutritional problems (sec-
ondary to macroglossia and pharynx involvement). Given the
inﬁltrative growth of these malformations, in all patients surgical
excision was incomplete, and the risk of recurrence was high.
Since the natural course of the disease could determine the
progressive enlargement of residual cysts resulting in compres-
sion of the adjacent structures, organ dysfunction or erosion of
the involved bones, a clinical, laboratory, and radiological
follow-up was mandatory. As we expected, the lesion continued
to grow after resection. Given the diffuse localization of the cystic
elements and the involvement of vital structures, surgery was not
applicable anymore. Sclerosing agents could not be injected
because of the surrounding vessels and because cysts were
numerous. Laser therapy was performed in one case to treat
superﬁcial localization in 1 patient (case 2). Therefore, in
our patients, the most suitable therapy was a systemic
pharmacological treatment. As reported in the recent literature,
sirolimus has been demonstrated to be effective in the treatment
of vascular anomalies, in particular in LMs and diffuse
lymphangiomatosis.[3,22–25]
In all patients, after starting sirolimus therapy, a remarkable
reduction in the size mass was demonstrated not only by the
physical examination but especially in the radiological investiga-
tion. There was an overall decrease inmass extension, a reduction
in cysts diameter and a global involution from macro- to the
microcystic composition. In one case (patient 4), the ﬁrst attempt
Table 2
Blood analysis before and during sirolimus treatment.
Case 1 Case 2 Case 3 Case 4
Time before/after 1 d 6 mo 1 d 5 mo 1 d 6 mo 2 mo 2.5 mo
Complete blood count
White blood cells, 103/mmc 8.73 15.25 18.56 11.87 16.33 10 13.66 7.07
Red blood cells, 106/mmc 3.21 4.95 4.78 5.23 4.51 5.18 3.64 5.23
Hemoglobin, g/dL 9.4 12 10.6 9.6 11.5 12.2 13.9 13.2
Hematocrit, % 28.1 35 33.3 31.4 33.2 35.3 40.9 39.9
Platelet, 103/mmc 503 522 257 483 199 243 325 630
Biochemistry
C reactive protein, mg/dL 0.25 0.38 0.33 0.04 0.07 0.03 0.03 0.02
Azotemia, mg/dL 12 21 33 25 31 26 31 17
Creatinine, mg/dL 0.14 0.25 0.21 0.21 0.51 0.44 0.8 0.24
Sodium, mEq/L 139 137 139 138 141 140 146 140
Potassium, mEq/L 5.1 6.2 4.8 5.3 5 3.5 3.7 5.1
Chloride, mEq/L 100 101 100 100 105 102 108 101
Calcium, mg/dL 10.31 10.34 10.07 9.87 10.27 10.43 9.36 10.75
Phosphate, mg/dL 6.6 5.2 5.1 5 6.1 4.9 5.2 6.2
AST, U/L 21 36 40 43 35 38 32 20
ALT, U/L 12 21 22 26 17 23 5 14
Alkaline phosphatase, U/L 265 195 252 187 287 276 161 275
Albumin, g/dL 3.7 4.5 4.5 4.1 4.6 4.9 3.3 3.7
Total cholesterol, mg/dL 119 226
∗
125 166 132 207
∗
126 173
LDL-C, mg/dL 67 166
∗




HDL-C, mg/dL 39 38 42 42 32 44 33 61
Triglycerides, mg/dL 86 108 52 92 84 178
∗
58 103
ALT= alanine aminotransferase, AST= aspartate aminotransferase, GGT=gamma-glutamyl transferase, HDL=high density lipoprotein cholesterol, LDL= low density lipoprotein cholesterol.
∗
Altered values.
Amodeo et al. Medicine (2017) 96:51 Medicinewith sirolimus was tried before surgical reduction of the mass
size, and no clinical improvement was demonstrated. The failure
of the initial treatment could be explained considering the broad
distribution of the cysts and the difﬁculties we had in reaching
and maintaining the desirable sirolimus blood levels. Indeed, the
treatment was suspended for several times, making sirolimus
ineffective. However, after surgical intervention, sirolimus was
restarted, and blood levels were sufﬁciently stable. A progressive
improvement was then observed.
Sirolimus was also effective in the treatment of diffuse
lymphangiomatosis (case 3), as already reported in the recent
literature.[24]
In the light of these considerations, we believe that sirolimus
treatment is effective in case of small cysts and when stable blood
levels can be maintained. In all other cases, a primary surgical
reduction of the mass size should be taken into consideration in
order to minimize the risk of ineffective pharmacological
treatment.
In our experience, sirolimus was practically and efﬁciently
managed by the patients’mothers. Compliancewas good, thanks
to the comfortable therapeutic scheme (oral administration 2
times/day). Sirolimus levels should be tested once a week in the
ﬁrst days of treatment. Once stable levels have been obtained,
blood levels could be tested every 2 weeks and then monthly.
Blood analysis should be performed monthly and should include
a complete blood count, azotemia, creatinine, electrolytes, uric
acid, albumin, total proteins, transaminase, total and fractioned
bilirubin, total cholesterol, LDL and HDL cholesterol, triglyc-
erides, C-reactive protein, immunoglobulins, lymphocytes
populations, and protein electrophoresis. Urine culture should
also be obtained. Blood analysis and cultures should be
performed at any time patient shows clinical signs of infection
or has new symptoms which could be related to sirolimus6treatment. As concerns radiological follow-up, we suggest to
perform a serial ultrasound, with a frequency depending on
radiological ﬁndings, and an MRI scan with contrast after 3 to 6
months therapy have been started. Themain and isolated adverse
effect we observed at laboratory analysis was progressive
dyslipidemia, with increasing levels of total cholesterol (in
particular LDL fractions) and triglycerides in 3 out of 4 patients.
No other complications secondary to sirolimus administration
were observed (Table 2).4. Conclusions
Sirolimus is a safe and effective therapy in the management of
multicystic and diffuse LMs. In particular, we recommend the use
of sirolimus after unsuccessful surgical excision have been tried or
when the surgical approach is not feasible, for example when
multiple localizations or diffuse lymphangiomatosis are present.
We suggest the therapeutic scheme of 0.4 to 0.8mg/m2 2 times/
day. The dosage should be adjusted to maintain sirolimus blood
levels between 10 and 15ng/mL. A multidisciplinary follow-up
should be started.
To date, our experience with sirolimus in the management of
LMs is favorable and poor disadvantages have been observed.
However, in our clinical records follow-up is limited and a longer
time is needed to monitor potential complications and disease
evolution.
Wewish for the use of sirolimus for the treatment of LMs could
be better characterized in the setting of a formal clinical trial.4.1. Informed Consent
The patient’s parents provided their written informed consent for
the publication of this case report.
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